RSV Prophylaxis for Newborn Infants Before Hospital Discharge
All newborns born during or entering their first RSV season (October through March in most of the continental United States) should receive a single dose of nirsevimab before hospital discharge, with weight-based dosing: 50 mg for infants <5 kg (<11 lb) and 100 mg for infants ≥5 kg (≥11 lb). 1
Timing of Administration
For infants born shortly before or during RSV season, administer nirsevimab within 1 week of birth. The medication can be given during the birth hospitalization or in the outpatient setting, but optimal timing is shortly before the RSV season begins 1.
Specific Timing Guidelines:
- Infants born during RSV season (October-March): Administer within the first week of life, ideally before hospital discharge 1
- Infants born April-September: Administer just before RSV season starts (late September to October) 2
- Preterm infants with prolonged hospitalizations: Give shortly before or promptly after hospital discharge 1
Dosing Algorithm
The dosing is straightforward and weight-based:
- <5 kg (<11 lb): 50 mg as single intramuscular injection
- ≥5 kg (≥11 lb): 100 mg as single intramuscular injection
Only one dose is needed per RSV season 1
Important Clinical Considerations
Use Chronologic Age for Preterm Infants
For premature infants, use chronologic (not corrected) age to determine timing and eligibility 1. This is a common pitfall—do not adjust for gestational age when calculating administration timing.
Coadministration with Vaccines
Nirsevimab can be administered simultaneously with routine childhood vaccines without increased adverse events or interference with vaccine immune response 1. This allows for efficient administration during well-child visits or before discharge.
Geographic Variations
RSV seasonality varies by region:
- Most continental US: October through March 1
- Tropical climates (southern Florida, Hawaii, Puerto Rico, Guam, US territories): Unpredictable patterns—consult local guidance 1
- Alaska: Less predictable with longer duration—follow state guidance 1
What NOT to Do
Nirsevimab is NOT recommended for prevention of hospital-acquired RSV infection 1. There is no evidence supporting its use for this indication. Do not administer monthly doses during prolonged hospitalizations as was done with palivizumab in older protocols 3, 4.
High-Risk Infants in Second RSV Season
For infants and children aged 8-19 months entering their second RSV season, nirsevimab (200 mg as two 100 mg injections at different sites) is recommended only for those at increased risk 1:
- Chronic lung disease requiring medical support in the 6 months before RSV season
- Severe immunocompromise
- Cystic fibrosis with severe manifestations
- American Indian/Alaska Native children 1
Safety Profile
Adverse events related to nirsevimab occur at rates similar to placebo (11% vs 10%) 5. The only contraindication is severe allergic reaction (anaphylaxis) to a previous dose or product component 1.
Practical Implementation
Real-world data from the 2025-2026 season showed 94% coverage when implemented systematically, with median administration at 3 days of age 6. However, preterm infants experienced delayed administration, emphasizing the need for discharge planning protocols that ensure timely prophylaxis before hospital discharge 6.
The evidence strongly supports universal prophylaxis for all eligible infants, representing a paradigm shift from the previous risk-based palivizumab approach that required monthly dosing 7.